Overview
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
Eligibility
Inclusion Criteria:
- hematologic malignancy patients
- patients eligible for the transplantation of allogeneic hematopoietic stem cells;
- patients unavailable with HLA matched donor or related haploidentical donor
- voluntary participation in this study and signing the informed consent form.
Exclusion Criteria:
- Patients with the severe infections;
- Pregnant or lactating women
- Patients who are not eligible for hematopoietic stem cell transplantation;
- Patients who are enrolled in other clinical trials within 1 month;
- Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study;
- Patients unable to properly understand or refusing to accept the informed consent form.
